Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE. (11th November 2022)

• Record Type: Journal Article
• Authors: Pirisino, Riccardo; Filippi, Luca; D'Agostini, Antonio; Bagni, Oreste
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 11(2022)
• Page Start: e692
• Page End: e695
• Publication Date: 2022-11-11
• Subjects: 177Lu-DOTATATE -- PRRT -- meningioma -- neuroendocrine tumor -- NET; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004307
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: A 76-year-old woman affected by pancreatic neuroendocrine tumor previously subjected to surgery with progressive liver disease and a concomitant mild symptomatic meningioma of the left pontocerebellar angle underwent 4 cycles of peptide receptor radionuclide therapy with 177 Lu-DOTATATE. A prophylactic therapy with corticosteroids was carried out before each treatment cycle, and the neurosurgery unit was alerted in case of cerebral edema and related neurologic symptoms. A 68 Ga-DOTATOC PET/CT scan performed after the completion of the 4 cycles' treatment documented a hepatic partial response and a substantial stability of the brain mass. No neurological complications occurred during treatment and follow-up.